loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Bezafibrate

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Bezafibrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 101Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Intercept: OCA-Bezafibrate Combo Data In PBC At EASL 2024
    Intercept: OCA-Bezafibrate Combo Data In PBC At EASL 2024

    05 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/05/2894098/23024/en/Intercept-Presents-New-Data-on-the-Results-of-OCA-Bezafibrate-Combination-Therapy-in-PBC-After-Six-Months-of-Treatment-in-Late-Breaking-Poster-Presentation-at-EASL-Congress-2024.html

    GLOBENEWSWIRE
    05 Jun 2024
    Share Share
    Intercept Shows OCA-Bezafibrate Combo Impact On ALP, Metabolic Outcomes
    Intercept Shows OCA-Bezafibrate Combo Impact On ALP, Metabolic Outcomes

    18 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/18/2884546/23024/en/Intercept-Presents-New-Data-Demonstrating-the-Impact-of-OCA-Bezafibrate-Combination-Therapy-on-ALP-and-Metabolic-Outcomes-After-Six-Months-of-Treatment-at-Digestive-Disease-Week-20.html

    GLOBENEWSWIRE
    18 May 2024
    Share Share
    Intercept Announces Phase 2 Data Showing Significant Impact of OCA-Bezafibrate
    Intercept Announces Phase 2 Data Showing Significant Impact of OCA-Bezafibrate

    13 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/13/2779021/23024/en/Intercept-Announces-New-Phase-2-Data-Showing-Significant-Impact-of-OCA-Bezafibrate-Combination-on-Normalization-of-Multiple-Key-Biomarkers-of-PBC-Induced-Liver-Damage-at-AASLD-The-.html

    GLOBENEWSWIRE
    13 Nov 2023
    Share Share
    Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate
    Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate

    23 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/23/2693415/23024/en/Intercept-Presents-New-Data-Showing-Significant-Impact-of-OCA-bezafibrate-Combination-on-Normalization-of-Multiple-Biomarkers-of-PBC-Induced-Liver-Damage.html

    GLOBENEWSWIRE
    23 Jun 2023
    Share Share
    Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA
    Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA

    07 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/07/2683624/23024/en/Intercept-Announces-New-Data-Showing-Potential-of-Fixed-Dose-Combination-of-OCA-and-Bezafibrate-to-Normalize-Multiple-Biomarkers-in-PBC-to-be-Featured-in-Podium-Presentation-at-EAS.html

    GLOBENEWSWIRE
    07 Jun 2023
    Share Share
    Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate
    Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate

    11 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/11/2440783/23024/en/Intercept-Announces-First-Patient-Dosed-in-Phase-2-Study-of-OCA-and-Bezafibrate-for-the-Treatment-of-Primary-Biliary-Cholangitis.html

    GLOBENEWSWIRE
    11 May 2022
    Share Share